Where can researchers source third-party tested SS-31?

Midwest Peptide supplies research-grade SS-31 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off when you pay with ZelleSave an extra 5% when you pay with Zelle

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

SS-31 Cardiac Ischemia-Reperfusion Research | Midwest Peptide

SS-31 Aging Research: Mitochondrial Decline StudiesPrev|Where to Buy SS-31 for Research: Elamipretide Sourcing GuideNext

SS-31 Cardiac Research: Ischemia-Reperfusion Studies

Q: Is SS-31 approved for human use?

No. SS-31 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

SS-31 · Published April 28, 2026 · Updated May 18, 2026 · 10 min read

Quick Answer

SS-31 cardiac research examines ischemia-reperfusion injury, infarct size reduction, and mitochondrial endpoints in rodent heart injury models. Studies measure cardiac function, mitochondrial bioenergetics, doxorubicin cardiotoxicity, and heart failure biomarkers across standardized cardiac research protocols using this cardiolipin-binding peptide. For research use only, not for human consumption.

SS-31 Cardiac Research: Ischemia-Reperfusion Studies

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

Why Cardiac Research Uses SS-31
Ischemia-Reperfusion Injury Biology
Animal Model Designs for Cardiac SS-31 Research
Infarct Size and Tissue Outcome Endpoints
Mitochondrial Endpoints in Cardiac Research
Heart Failure and Chronic Cardiac Stress Research
Doxorubicin Cardiotoxicity Research
Comparison with Other Mitochondrial-Targeted Compounds in Cardiac Research
Timing of Administration in Cardiac Research
Methodology Considerations for Cardiac Research
Open Questions in Cardiac SS-31 Research
Research Peptides Referenced
Related Research Reading
Frequently Asked Questions
Glossary

SS-31 cardiac research has accumulated one of the largest single-disease bodies of literature in the mitochondrial peptide field, with published animal-model studies examining the Szeto-Schiller tetrapeptide across ischemia-reperfusion injury, heart failure models, doxorubicin cardiotoxicity, and various other cardiac stress contexts. This article reviews the published cardiac research on SS-31 10mg as a research-grade reference compound, with attention to the ischemia-reperfusion injury framework, the mitochondrial mechanisms relevant to cardiac protection, and the methodological practices that produce informative cardiac data. For the broader SS-31 context see the SS-31 research cluster.

Frequently Asked Questions

What is SS-31 in research contexts?

SS-31 (elamipretide) is a synthetic four-amino-acid Szeto-Schiller tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane. It is studied in preclinical research for cristae stabilization, mitochondrial bioenergetics, and ischemia-reperfusion injury.

How does SS-31 protect against ischemia-reperfusion injury?

SS-31 binding to cardiolipin stabilizes the inner mitochondrial membrane during reperfusion, preserving electron transport chain integrity and reducing reactive oxygen species generation that drives reperfusion injury. The peptide reduces infarct size in cardiac ischemia models.

What cardiac models are used in SS-31 research?

Models include left anterior descending coronary artery occlusion in rodents, ex vivo Langendorff heart preparations, isolated cardiomyocyte hypoxia-reoxygenation, doxorubicin cardiotoxicity, and chronic heart failure models. Endpoints span function, infarct size, and mitochondrial integrity.

Is SS-31 approved for human use?

Glossary

Key terms used in this article.

Cardiolipin: A unique phospholipid concentrated in the inner mitochondrial membrane that is essential for cristae structure and electron transport chain function.
Cristae: The folded inner membrane structures of mitochondria where the electron transport chain and ATP synthase reside.
Inner Mitochondrial Membrane (IMM): The highly folded mitochondrial membrane that hosts the electron transport chain and maintains the proton gradient for ATP synthesis.
Ischemia-Reperfusion Injury: Tissue damage caused when blood supply returns to tissue after a period of ischemia, driven largely by mitochondrial ROS.
Elamipretide: The international nonproprietary name for SS-31, a cardiolipin-targeted mitochondrial peptide in clinical research.
Reperfusion Injury: The tissue damage that occurs when blood flow returns after ischemia, driven largely by mitochondrial ROS production.
Langendorff Preparation: An ex vivo isolated heart perfusion system widely used in cardiac research.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. SS-31 is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of an authorized research protocol.

Why Cardiac Research Uses SS-31

Cardiomyocytes have one of the highest mitochondrial densities of any cell type, with mitochondria occupying roughly a third of the cellular volume in adult ventricular myocytes. The heart depends almost entirely on aerobic metabolism for its energy supply, with continuous ATP synthesis required to support contraction. Mitochondrial dysfunction is therefore a recurring theme in cardiac disease research, and interventions that preserve or restore mitochondrial function are a research target that connects mechanism to function in a particularly direct way.

SS-31 is well positioned for cardiac research because the mechanism (cardiolipin binding, cristae stabilization, supercomplex preservation, mPTP attenuation) is mechanistically aligned with the mitochondrial dysfunction that drives cardiac injury under stress conditions. Published cardiac research with SS-31 documents effects across multiple endpoints in standardized animal-model designs, making it one of the most extensively characterized research compounds in the cardiac mitochondrial literature. For an extended discussion of the mechanism, see our companion article on SS-31 mechanism of action and cardiolipin binding research.

Ischemia-Reperfusion Injury Biology

Ischemia-reperfusion injury is the central concept in much of the cardiac SS-31 research. The injury process has two phases. During ischemia (cessation of blood flow), oxygen and nutrient delivery to the affected tissue stops, ATP synthesis ceases as electron transport substrates are depleted, intracellular calcium accumulates, and the tissue enters a stress state that is reversible up to a point but progresses toward cell death with prolonged ischemia. During reperfusion (return of blood flow), the rapid resupply of oxygen to ischemic tissue triggers a paradoxical phase of injury that is mechanistically distinct from the ischemic phase itself.

Reperfusion injury is driven by a burst of mitochondrial ROS production, calcium overload from the resumption of electron transport in compromised mitochondria, and opening of the mitochondrial permeability transition pore (mPTP). mPTP opening collapses the membrane potential, releases pro-apoptotic factors, and commits the cell to death. The protection of cardiomyocytes from reperfusion injury is therefore a central research target, and SS-31 effects on the upstream mitochondrial events (preserved cristae, reduced ROS production, attenuated mPTP opening) translate to reduced infarct size and preserved cardiac function in animal-model studies.

The Cell Press journal Cell Reports and the ScienceDirect topic page on ischemia reperfusion archive primary research on ischemia-reperfusion biology relevant to the SS-31 cardiac literature.

Animal Model Designs for Cardiac SS-31 Research

The published cardiac SS-31 literature uses several standardized animal-model designs. Coronary artery ligation models produce controlled myocardial ischemia by surgically occluding a coronary artery for a defined duration, then releasing the occlusion to induce reperfusion. Common variations include left anterior descending (LAD) artery ligation in rodent models, with infarct size measured by triphenyl tetrazolium chloride (TTC) staining of the at-risk and infarcted regions. Larger animal models (rabbit, pig) use similar designs with adjusted anatomical considerations.

Isolated heart preparations (Langendorff perfusion, working heart) provide ex vivo platforms for cardiac SS-31 research with controlled perfusate composition and direct cardiac output measurements. These preparations are useful for mechanism studies because they remove systemic confounders and allow direct correlation of perfusate composition with cardiac function. Cell-based cardiomyocyte models (primary adult cardiomyocytes, neonatal cardiomyocytes, induced pluripotent stem cell-derived cardiomyocytes) provide further reductionist platforms for mechanism studies.

Each model contributes distinct information to the cumulative cardiac literature. Cellular models support mechanistic depth. Isolated heart preparations support functional integration. In vivo animal models support the systemic context. Research designs that combine multiple model systems generate the most informative integrated data.

Infarct Size and Tissue Outcome Endpoints

Infarct size is the most frequently reported endpoint in cardiac SS-31 research because it is the most direct measure of tissue damage. Published research documents reduced infarct size in SS-31 treated animals compared with vehicle controls across multiple ischemia-reperfusion designs. The magnitude of effect varies with the experimental conditions, including the duration of ischemia, the timing of SS-31 administration relative to ischemia and reperfusion, and the species used.

The reduction in infarct size is mechanistically linked to the preserved mitochondrial function in the at-risk myocardium. Cardiomyocytes that maintain mitochondrial structural integrity during reperfusion can resume oxidative phosphorylation, support continued contraction, and avoid the mPTP-driven cell death that would otherwise occur. The integrated tissue outcome reflects the cumulative protection across the affected myocardial region.

Beyond infarct size, the cardiac SS-31 literature includes histological endpoints (cardiomyocyte apoptosis markers, fibrosis markers in chronic studies), biochemical endpoints (cardiac troponin release, BNP levels), and functional endpoints (echocardiographic measurements of ejection fraction, wall motion, chamber dimensions). Research designs that combine endpoints across these levels characterize the integrated cardiac protection profile.

The Frontiers in Cardiovascular Medicine archives primary research on cardiac protection relevant to the SS-31 literature.

Mitochondrial Endpoints in Cardiac Research

Cardiac SS-31 research that includes mitochondrial endpoints alongside tissue endpoints generates particularly informative mechanism data. Mitochondrial endpoints include respiration measurements on isolated cardiac mitochondria (state 3 and state 4 respiration, respiratory control ratio), ATP synthesis assays, ROS production measurements, electron microscopy of cristae architecture, and blue-native PAGE analysis of supercomplex composition.

Published research documents preserved cardiac mitochondrial respiration in SS-31 treated animals, maintained cristae architecture in stressed myocardium, preserved supercomplex assembly, and reduced ROS production from cardiac mitochondria during reperfusion. The mitochondrial endpoints connect mechanistically to the tissue endpoints and document the relationship between upstream mitochondrial protection and downstream tissue outcome.

The Wiley Online Library cardiac mitochondrial research collection archives primary research on cardiac mitochondrial biology relevant to the SS-31 literature.

Heart Failure and Chronic Cardiac Stress Research

Beyond acute ischemia-reperfusion, SS-31 has been examined in chronic cardiac stress models including pressure overload, volume overload, and post-infarct remodeling. These models examine the role of mitochondrial function in the chronic adaptation of the heart to sustained stress. Mitochondrial dysfunction is documented in failing hearts across multiple etiologies, with reduced respiratory capacity, altered cristae architecture, and increased ROS production characterizing the failing myocardium.

Published SS-31 research in chronic cardiac stress models documents effects on the progression of cardiac dysfunction, including preserved cardiac function in pressure-overload models, reduced fibrosis markers, and preserved mitochondrial function in chronically stressed myocardium. The chronic cardiac literature is smaller than the acute ischemia-reperfusion literature but represents a distinct research vein where the mitochondrial-targeted mechanism produces relevant functional benefits.

Doxorubicin Cardiotoxicity Research

Doxorubicin is an anticancer agent with documented cardiotoxicity that operates through mitochondrial mechanisms. The drug accumulates in cardiac mitochondria, generates ROS through redox cycling, damages cardiolipin, and produces progressive mitochondrial dysfunction that translates to chronic cardiac damage in animal-model studies. The mechanism overlap with the SS-31 protective framework (cardiolipin protection, ROS reduction) makes doxorubicin cardiotoxicity a relevant research model for SS-31 effects.

Published research in doxorubicin cardiotoxicity models documents preserved cardiac mitochondrial function in SS-31 treated animals, reduced cardiac dysfunction over the course of doxorubicin exposure, and maintained cardiomyocyte viability in cardiac tissue. The doxorubicin literature complements the ischemia-reperfusion literature by documenting protective effects in a distinct injury context with a different upstream cause.

Comparison with Other Mitochondrial-Targeted Compounds in Cardiac Research

The cardiac SS-31 literature includes comparison work with other mitochondrial-targeted research compounds. The MOTS-C research cluster covers the mitochondrially encoded peptide that engages metabolic signaling rather than direct membrane protection. Comparison work between SS-31 and MOTS-C in cardiac models documents that SS-31 produces particularly strong effects on ischemia-reperfusion endpoints because of the mechanism alignment with the injury biology, while MOTS-C contributes through metabolic regulation effects on cardiomyocyte function.

For an extended discussion of the SS-31 versus MOTS-C comparison, see our companion article on SS-31 vs MOTS-C mitochondrial peptide comparison research. The cardiac research also intersects with NAD+ research on the central coenzyme of cardiac metabolism and glutathione research on the master antioxidant relevant to cardiac redox biology.

Timing of Administration in Cardiac Research

A methodological theme in cardiac SS-31 research is the timing of administration relative to ischemia and reperfusion. Pretreatment designs administer SS-31 before ischemia, allowing mitochondrial accumulation to reach steady state before the injury. At-reperfusion designs administer SS-31 at the moment of reperfusion to address the reperfusion injury phase specifically. Post-reperfusion designs examine recovery from established injury. Each timing design contributes distinct information about the protective profile.

The published timing comparison work documents that pretreatment produces the largest protective effects because the mitochondria are protected from the outset of the injury. At-reperfusion administration produces meaningful but smaller effects because the early phase of reperfusion injury can occur before therapeutic concentrations are reached. Post-reperfusion administration produces effects on recovery but does not prevent the initial injury. The timing comparison informs research design decisions about when to administer SS-31 in different injury contexts.

Methodology Considerations for Cardiac Research

Cardiac SS-31 research is most informative when the methodology supports the integrated interpretation. Standardized injury production with consistent ischemia duration and reperfusion timing produces comparable data across studies. Blinded analysis of imaging and histological endpoints reduces observer bias. Predefined primary endpoints prevent post-hoc analysis from distorting the comparison. Sample size calculations based on expected effect sizes ensure adequate statistical power. Integrated reporting that combines tissue, mitochondrial, and functional endpoints generates the most informative cumulative data.

Reference compound quality is particularly important for cardiac research because the experimental designs are demanding and the endpoints can be sensitive to material that does not match the expected sequence. For sourcing considerations, see our companion article on where to buy SS-31 for research and the elamipretide sourcing guide.

Open Questions in Cardiac SS-31 Research

Several open questions remain in cardiac SS-31 research. The optimal dosing strategy for chronic cardiac stress models is incompletely characterized in the public literature, with most published work using acute or short-term dosing. The mechanism connection between mitochondrial protection and the reduction of post-infarct fibrosis is incompletely resolved, with several candidate mechanisms (preserved cardiomyocyte viability, altered fibroblast behavior, modulated inflammatory milieu) that require further discrimination. The applicability of findings from rodent models to larger animal models and across species is also incompletely characterized for the chronic cardiac applications.

These open questions create opportunities for new cardiac research that contributes to the cumulative literature. Research programs that include integrated endpoints, multiple species, and well-characterized reference compounds generate the most informative data.

Research Peptides Referenced

SS-31 10mg, research grade Szeto-Schiller mitochondrially targeted tetrapeptide
MOTS-C 10mg, comparator mitochondrial peptide for cardiac research
NAD+ 500mg, central coenzyme of cardiac mitochondrial metabolism
Glutathione 1500mg, antioxidant comparator for cardiac redox research

For complete sourcing details see the SS-31 sourcing guide.

Within the SS-31 cluster:

Related clusters:

Not for human consumption. Research use only.

Age Verification

SS-31 Cardiac Research: Ischemia-Reperfusion Studies

Frequently Asked Questions

What is SS-31 in research contexts?

How does SS-31 protect against ischemia-reperfusion injury?

What cardiac models are used in SS-31 research?

Is SS-31 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Why Cardiac Research Uses SS-31

Ischemia-Reperfusion Injury Biology

Animal Model Designs for Cardiac SS-31 Research

Infarct Size and Tissue Outcome Endpoints

Mitochondrial Endpoints in Cardiac Research

Heart Failure and Chronic Cardiac Stress Research

Doxorubicin Cardiotoxicity Research

Comparison with Other Mitochondrial-Targeted Compounds in Cardiac Research

Timing of Administration in Cardiac Research

Methodology Considerations for Cardiac Research

Open Questions in Cardiac SS-31 Research

Research Peptides Referenced

Ready to Start Your Research?

Where can researchers source third-party tested SS-31?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

SS-31 Cardiac Research: Ischemia-Reperfusion Studies

Frequently Asked Questions

What is SS-31 in research contexts?

How does SS-31 protect against ischemia-reperfusion injury?

What cardiac models are used in SS-31 research?

Is SS-31 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Why Cardiac Research Uses SS-31

Ischemia-Reperfusion Injury Biology

Animal Model Designs for Cardiac SS-31 Research

Infarct Size and Tissue Outcome Endpoints

Mitochondrial Endpoints in Cardiac Research

Heart Failure and Chronic Cardiac Stress Research

Doxorubicin Cardiotoxicity Research

Comparison with Other Mitochondrial-Targeted Compounds in Cardiac Research

Timing of Administration in Cardiac Research

Methodology Considerations for Cardiac Research

Open Questions in Cardiac SS-31 Research

Research Peptides Referenced

Related Research Reading

Ready to Start Your Research?

Where can researchers source third-party tested SS-31?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?